|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial显示文摘 | Axel Grothey Eric Van Cutsem Alberto Sobrero Salvatore Siena Alfredo Falcone Marc Ychou Yves Humblet Olivier Bouché Laurent Mineur Carlo Barone Antoine Adenis Josep Tabernero Takayuki Yoshino Heinz-Josef Lenz Richard M Goldberg Daniel J Sargent Frank Ciho | 2012 | The Lancet2012，，： | 10 |
| 2 | Uncertainty and the market valuation of R&~D within a real options logic 显示文摘 | Oriani R Sobrero M | 2008 | Strategic Management Journal2008，29，： | 1 |
| 3 | Raltitrexed (tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 ( PETACC-1 ) 显示文摘 | Popov I Garrato A Sobrero A | 2008 | European Journal of Cancer2008，44，15： | 1 |
| 4 | Evidence for cure by adju- vant therapy in colon cancer: observations based on individual pa- tient data from 20,898 patients on 18 randomized trials显示文摘 | Sargent D Sobrero A Grothey A | 2009 | J Clin Oncol2009，27，6： | 1 |
| 5 | Regorafenibmonotherapy for previously treated metastatic colorectalcancer (CORRECT): an international, multicentre,ran-domised, placebo- controlled, phase 3 trial 显示文摘 | Grothey A Cutsem EV Sobrero A | 2013 | Lancet2013，381，9863： | 1 |
| 6 | Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, ran- domised, placebo-controlled, phase 3 trial显示文摘 | Grothey A Van Cutsem E Sobrero A | 2013 | Lancet2013，381，9863： | 1 |
| 7 | Phase Ⅱ study of NGR-hTNF,a selective vascular targeting agent,in patients with metastatic colorectal cancer after failure of standard therapy显示文摘 | Santoro A Rimassa L Sobrero AF | 2010 | Eur J Cancer2010，46，15： | 1 |
| 8 | EPIC: Phase Ⅲ trial of cetuximab plus irinotecan after fluoropyfimidine and oxaliplatin failure in patients with metastatic eolorectal cancer 显示文摘 | Sobrero AF Maurel J Fehmnbacher L | 2008 | J Clin Oncol2008，26，14： | 1 |
| 9 | Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20898 patients on 18 randomized trials 显示文摘 | Sargent DJ Sobrero A Grothey A | 2009 | J Clin Oncol2009，27，6： | 1 |
| 10 | Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer: economic evaluation in an Italian NHS setting 显示文摘 | Di Costanzo F Ravasio R Sobrero A | 2008 | Clin DrugInvestig2008，28，10： | 1 |
| 11 | EPIC:phase Ⅲ trial of cemximab plus irinotecan after fluoropyrimidine and oxalipla-tin failure in patients with metastatic colorectal cancer显示文摘 | AIberto F Maurel Joan | 2008 | J Clin Oncol2008，26，14： | 1 |
| 12 | Fluorouracil in colorectal cancer-- a tale of two drugs: implications for biochemical modulation显示文摘 | Sobrero AF Aschele C Bertino JR | 1997 | J Clin Oncol1997，15，1： | 1 |
| 13 | EPIC:PhaseⅢtrial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer显示文摘 | Sobrero A F Maurel J Fehrenbacher L | 2008 | J Clin Oncol2008，26，14： | 1 |
| 14 | Schedule - dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro 显示文摘 | Aschele C Baldo C Sobrero AF | 1998 | Clin Cancer Res1998，4，5： | 1 |
| 15 | Spectrophoto- metric determination of sorbic and benzoic acids in fruit juices by a net analyte signal-based method with selection of the wavelength range to avoid non-modelled interferences 显示文摘 | Marsili N R Sobrero M S Goicoechea H C | 2003 | Analytical and Bioanalytical Chemistry2003，376，1： | 1 |
| 16 | Intermittent versus continunus chemotherapy in advanced colorectal cancer:a randomised 'GISCAD' trial显示文摘 | Labianca R Sobrero A Isa L | | 0，，： | 1 |
| 17 | Uncertainty and the market valuation of R&D within a real options logic显示文摘 | R ORIANI M SOBRERO | 2008 | Strategic Management Journal2008，，4： | 1 |
| 18 | Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double- blind,randomized phase Ⅲ study ( HORIZON Ⅲ ) 显示文摘 | Schmoll HJ Cunningham D Sobrero A | 2012 | J Clin Oncol2012，30，29： | 1 |
| 19 | Schedule-dependent synergism between raltitrexed and irinotecan in human coloncancer cells in vitro显示文摘 | Aschele C Baldo C Sobrero A F | 1998 | Clin Cancer Res1998，4，5： | 1 |
| 20 | Fluorouracil in colorectal cancer-a tale of two drugs: implications for biochemical modulation 显示文摘 | Sobrero AF Aschele C Bertino JR | 1997 | J Clin Oncol1997，15，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员